Functional Art: How Custom-Designed Stainless Steel Trash Bins Enhance Modern Interior Architecture

JIANGMEN, GUANGDONG, CHINA, January 26, 2026 /EINPresswire.com/ -- Modern interior architecture often emphasizes grand ...
Morning Overview on MSN

RNA strand that nearly self-replicates could unlock life’s origin

A 45-nucleotide strand of RNA can now synthesize both its mirror-image complement and a copy of itself, bringing scientists closer than ever to demonstrating how life could have emerged from chemistry ...

Sena Mesh Intercom Adapter Available Through OEM GPS Navigation

This addition provides enhanced communication options for motorcyclists, allowing for integrated use of intercom devices and […] ...
Pharmabiz

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy

Omeros Corporation, an innovative biotechnology company, announced that the US Food and Drug Administration (FDA) has approved Yartemlea (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...
FiercePharma

Omeros scores its 1st FDA nod as stem cell transplant drug Yartemlea approved

It's been a long time coming: Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the Seattle biotech has finally scored its ...
The Pharma Letter

Omeros rockets as FDA approves Yartemlea

Seattle, USA-based biotech Omeros Corp (Nasdaq: OMER) saw its shares leap 75.5% to $15.36 by close of trading Wednesday, as it revealed that the US Food and Drug Administration (FDA) has approved its ...
Seeking Alpha

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic ...
MarketWatch

FDA Approves Omeros' YARTEMLEA(R) -- First and Only Therapy Indicated for TA-TMA

The MarketWatch News Department was not involved in the creation of this content. -- Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: ...
Nasdaq

Omeros Wins FDA Approval For YARTEMLEA In Transplant-Associated Thrombotic Microangiopathy

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...
MarketWatch

Omeros Gets FDA Approval of Yartemlea

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...
WebMD

What Is Complement 3 Glomerulopathy?

Also called C3G, this rare kidney disease often affects children and young adults, but it can happen at any age. It has a major impact on a person’s health and life. C3G has two forms: dense deposit ...